Valerie Delecroix
Overview
Explore the profile of Valerie Delecroix including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Joly F, Bazan F, Garbay Decoopman D, Garbay D, Ouldbey Y, Follana P, et al.
JNCI Cancer Spectr
. 2024 Dec;
9(1).
PMID: 39673810
Background: Maintenance niraparib at an individualized starting dose (ISD) is established in platinum-sensitive recurrent ovarian cancer (PSROC). However, patients' perspectives on the burden of prolonged maintenance therapy have not been...
2.
Gac M, Loaec C, Silve J, Vaucel E, Augereau P, Wernert R, et al.
Eur J Surg Oncol
. 2020 Sep;
47(2):360-366.
PMID: 32863097
Objectives: In 2016, the European Society of Gynecology Oncology (ESGO) published indicators defining the quality of surgical management of advanced ovarian cancer. The objective of the study was to assess...
3.
Voog E, Campillo-Gimenez B, Elkouri C, Priou F, Rolland F, Laguerre B, et al.
Int J Cancer
. 2019 Jul;
146(6):1643-1651.
PMID: 31318983
The treatment landscape in metastatic renal cell carcinoma has changed fundamentally over the last decade by the development of antiangiogenic agents, mammalian target of rapamycin inhibitors and immunotherapy. Outside of...
4.
Curtit E, Pivot X, Henriques J, Paget-Bailly S, Fumoleau P, Rios M, et al.
Breast Cancer Res
. 2017 Aug;
19(1):98.
PMID: 28830573
Background: Genome-wide association studies (GWAS) have to date identified 94 genetic variants (single nucleotide polymorphisms (SNPs)) associated with risk of developing breast cancer. A score based on the combined effect...
5.
Pivot X, Romieu G, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, et al.
NPJ Breast Cancer
. 2017 Jun;
3:4.
PMID: 28649644
Human epidermal growth factor receptor 2-positive breast cancer is a subtype of interest regarding its outcome and the impressive impact of human epidermal growth factor receptor 2 targeted therapy. Constitutional...
6.
Cox D, Curtit E, Romieu G, Fumoleau P, Rios M, Bonnefoi H, et al.
Oncotarget
. 2016 Oct;
7(47):77358-77364.
PMID: 27764800
Genetic polymorphisms are associated with breast cancer risk. Clinical and epidemiological observations suggest that clinical characteristics of breast cancer, such as estrogen receptor or HER2 status, are also influenced by...
7.
Falandry C, Horard B, Bruyas A, Legouffe E, Cretin J, Meunier J, et al.
Aging (Albany NY)
. 2015 Dec;
7(12):1066-76.
PMID: 26638179
Purpose: Age induces a progressive decline in functional reserve and impacts cancer treatments. Telomere attrition leads to tissue senescence. We tested the hypothesis that telomere length (TL) could predict patient...
8.
Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, et al.
J Clin Oncol
. 2006 Nov;
24(34):5366-72.
PMID: 17088570
Purpose: This study aimed to assess prospectively the efficacy of sequential [18F]fluorodeoxyglucose positron emission tomography (FDG PET) to evaluate early response to neoadjuvant chemotherapy in stage II and III breast...